The Pharmacy Times® Oncology Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to oncology pharmacists.
April 14th 2025
Current treatment strategies are aimed at reducing hematocrit and symptom burden through phlebotomy, aspirin, and cytoreductive agents, while emerging therapies offer promise for better disease control and quality of life.
Sanofi Halves the Price of Zaltrap in Response to Criticism from Oncologists
November 13th 2012Sanofi slashed the price of colorectal cancer drug Zaltrap (ziv-aflibercept) in half after 2 oncologists from Memorial Sloan-Kettering Cancer Center publicly balked at the drug's $11,000 price tag in an op-ed in The New York Times.
Read More
The Specialty Pharmacy Pipeline: What's Next?
October 17th 2012In a session at the 2012 Academy of Managed Care Pharmacy Educational Conference, Aimee Tharaldson, PharmD, identified the top specialty drugs in the pipeline and highlighted the most recent therapeutic trends within each medication class.
Read More
FDA Approves Abraxane as a First-Line Treatment for Advanced Non-Small Cell Lung Cancer
October 12th 2012Celgene Corporation today announced the FDA has approved Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) as a first-line treatment for locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
Read More
Symptom Relief from Breakthrough Cancer Pain: An Evaluation of Patient Satisfaction
September 13th 2012Breakthrough cancer pain-episodes of intense pain experienced by many cancer patients despite around-the-clock treatment with opioids-can be effectively managed with a fentanyl-based oral spray.
Read More
New FDA Actions: Genetech's Erivedge
September 12th 2012The FDA approved Genetech's Erivedge (vismodegib) capsules for the treatment of adult patients with metastatic basal cell carcinoma(BCC) or with locally advanced BCC that has recurred following surgery, and for patients who are not candidates for radiation.
Read More